الرئيسية التحكم التسجيل
 

 
 
العودة   منتديات الكيمياء الحيوية للجميع > الاقسام الاكاديمية > الأبحاث المنشورة - Published Researchs
 
 

الأبحاث المنشورة - Published Researchs ملخصات للابحاث المنشوره في مواضيع الكيمياء الحيوية

إضافة رد
 
 
 
أدوات الموضوع انواع عرض الموضوع
 
 
 
 
قديم 07-13-2008, 03:41 AM   #1
faridhalim20
بيوكيميائي ذهبي
 
الصورة الرمزية faridhalim20

 









faridhalim20 غير متواجد حالياً
افتراضي Proteomics

Proteomics

Citation Citation Score
1. Serum protein fingerprinting coupled with a pattern-matching algorithm distinguishes prost Cancer Res 62: 3609-14. (2002).

987.5

2. Proteomics and bioinformatics approaches for identification of serum biomarkers to detect Clin Chem 48: 1296-304. (2002).

906.2

3. Mass spectrometry as a diagnostic and a cancer biomarker discovery tool: opportunities and Mol Cell Proteomics 3: 367-78. (2004).

800.0

4. Proteomic applications for the early detection of cancer. Nat Rev Cancer 3: 267-75. (2003).

722.2

5. Three biomarkers identified from serum proteomic analysis for the detection of early stage Cancer Res 64: 5882-90. (2004).

650.0

6. Disease proteomics. Nature 422: 226-32. (2003).

620.0

7. Boosted decision tree analysis of surface-enhanced laser desorption/ionization mass spectr Clin Chem 48: 1835-43. (2002).

500.0

8. Toward a human blood serum proteome: analysis by multidimensional separation coupled with Mol Cell Proteomics 1: 947-55. (2002).

435.7

9. Mining the plasma proteome for cancer biomarkers. Nature 452: 571-9. (2008).

402

10. The prognostic molecular markers in hepatocellular carcinoma. World J Gastroenterol 8: 385-92. (2002).

386.7

11. The human serum proteome: display of nearly 3700 chromatographically separated protein spo Proteomics 3: 1345-64. (2003).

385.7

12. Haptoglobin-alpha subunit as potential serum biomarker in ovarian cancer: identification a Clin Cancer Res 9: 2904-11. (2003).

328.6

13. Proteomics applied to the clinical follow-up of patients after allogeneic hematopoietic st Blood 104: 340-9. (2004).

300.0

14. Development of a novel proteomic approach for the detection of transitional cell carcinoma Am J Pathol 158: 1491-502. (2001).

300.0

15. Diagnostic potential of serum proteomic patterns in prostate cancer. J Urol 170: 442-6. (2003).

271.4

16. Proteomic characterization of the interstitial fluid perfusing the breast tumor microenvir Mol Cell Proteomics 3: 327-44. (2004).

266.7

17. Proteomic approaches to tumor marker discovery. Arch Pathol Lab Med 126: 1518-26. (2002).

264.3

18. Biomarkers in cancer staging, prognosis and treatment selection. Nat Rev Cancer 5: 845-56. (2005).

261

19. How are we going to discover new cancer biomarkers? A proteomic approach for bladder cance Clin Chem 50: 793-5. (2004).

258

20. Cancer biomarkers--an invitation to the table. Science 312: 1165-8. (2006).

252

21. Identification of serum amyloid a protein as a potentially useful biomarker to monitor rel Clin Cancer Res 10: 43-52. (2004).

250.0

22. SELDI proteinchip MS: a platform for biomarker discovery and cancer diagnosis. Expert Rev Mol Diagn 2: 549-63. (2002).

244

23. Genome-Scale Proteomics Reveals Arabidopsis thaliana Gene Models and Proteome Dynamics. Science 0: . (2008).

239

24. Characterization of the human urinary proteome: a method for high-resolution display of ur Proteomics 4: 1159-74. (2004).

233.3

25. How industry is approaching the search for new diagnostic markers and biomarkers. Mol Cell Proteomics 3: 345-54. (2004).

233.3

26. Proteomics in early detection of cancer. Clin Chem 47: 1901-11. (2001).

231.8

27. A panel of cerebrospinal fluid potential biomarkers for the diagnosis of Alzheimer's disea Proteomics 3: 1486-94. (2003).

228.6

28. Direct quantitative trait locus mapping of mammalian metabolic phenotypes in diabetic and Nat Genet 0: . (2007).

223

29. Proteomic analysis and identification of new biomarkers and therapeutic targets for invasi Proteomics 2: 76-84. (2002).

222.2

30. Characterization of renal allograft rejection by urinary proteomic analysis. Ann Surg 237: 660-4; discussi. (2003).

211.1

31. Identification of biomarkers for breast cancer in nipple aspiration and ductal lavage flui Clin Cancer Res 11: 8312-20. (2005).

207

32. Identification of a new marker of hepatocellular carcinoma by serum protein profiling of p Hepatology 41: 40-7. (2005).

200.0

33. Engineered antibody fragments and the rise of single domains. Nat Biotechnol 23: 1126-36. (2005).

198

34. In biomarkers we trust? Nat Biotechnol 23: 297-304. (2005).

198

35. Metabolomic Identification of Novel Biomarkers of Myocardial Ischemia. Circulation 0: . (2005).

191

36. Biomarkers of cardiovascular disease: molecular basis and practical considerations. Circulation 113: 2335-62. (2006).

191

37. {beta}2-Microglobulin as a Biomarker in Peripheral Arterial Disease. Proteomic Profiling a Circulation 0: . (2007).

191

38. Serum biomarkers of hepatitis B virus infected liver inflammation: a proteomic study. Proteomics 3: 666-74. (2003).

188.9

39. Proteomic approaches to biomarker discovery in prostate and bladder cancers. Proteomics 1: 1264-70. (2001).

186.4

40. Antibody microarray profiling of human prostate cancer sera: antibody screening and identi Proteomics 3: 56-63. (2003).

180.0

41. Identification of biochemical adaptations in hyper- or hypocontractile hearts from phospho Proc Natl Acad Sci U S A 101: 2241-6. (2004).

175.0

42. Microarrays as cancer keys: an array of possibilities. J Clin Oncol 20: 3165-75. (2002).

175.0

43. Protein biomarker discovery and validation: the long and uncertain path to clinical utilit Nat Biotechnol 24: 971-83. (2006).

173

44. Discovery of Candidate Tumor Markers for Prostate Cancer via Proteomic Analysis of Cell Cu Clin Chem 0: . (2007).

171

45. Serum peptidome for cancer detection: spinning biologic trash into diagnostic gold. J Clin Invest 116: 26-30. (2006).

169

46. HDL proteomics: pot of gold or Pandora's box? J Clin Invest 117: 595-8. (2007).

165

47. Nutrigenomics: exploiting systems biology in the nutrition and health arena. Curr Opin Biotechnol 13: 517-21. (2002).

164.3

48. A software suite for the generation and comparison of peptide arrays from sets of data col Mol Cell Proteomics 4: 1328-40. (2005).

163

49. Molecular staging of prostate cancer in the year 2007. World J Urol 0: . (2007).

162

50. Two-dimensional liquid separations-mass mapping of proteins from human cancer cell lysates J Chromatogr B Analyt Technol Biomed Life Sci 782: 183-96. (2002).

158

51. Peptidomics and proteomics studies of transformed lymphocytes from patients mutated for th J Chromatogr B Analyt Technol Biomed Life Sci 0: . (2006).

158

52. Application of proteomic technologies to discover and identify biomarkers for excessive al J Chromatogr B Analyt Technol Biomed Life Sci 0: . (2007).

158

53. Biomarker discovery for kidney diseases by mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci 0: . (2007).

158

54. Statistical data processing in clinical proteomics. J Chromatogr B Analyt Technol Biomed Life Sci 0: . (2007).

158

55. Characterization of the mouse bronchoalveolar lavage proteome by micro-capillary LC-FTICR J Chromatogr B Analyt Technol Biomed Life Sci 0: . (2008).

158

56. Proteomic approaches in the search for disease biomarkers. J Chromatogr B Analyt Technol Biomed Life Sci 814: 11-9. (2005).

157

57. Proteomics delivers on promise of cancer biomarkers. Nat Med 9: 980. (2003).

156

58. Predicting the clinical outcome of congenital unilateral ureteropelvic junction obstructio Nat Med 0: . (2006).

156

59. Genomics and proteomics: Emerging technologies in clinical cancer research. Crit Rev Oncol Hematol 0: . (2006).

156

60. Differential exoprotease activities confer tumor-specific serum peptidome patterns. J Clin Invest 116: 271-84. (2006).

153

61. Mass spectrometry-based expression profiling of clinical prostate cancer. Mol Cell Proteomics 4: 545-54. (2005).

152

62. Identification and proteomic profiling of exosomes in human urine. Proc Natl Acad Sci U S A 101: 13368-73. (2004).

150.0

63. Identification of post-mortem cerebrospinal fluid proteins as potential biomarkers of isch Proteomics 4: 2234-41. (2004).

150.0

64. Detection of cancer-specific markers amid massive mass spectral data. Proc Natl Acad Sci U S A 100: 14666-71. (2003).

150.0

65. Proteomic analysis of normal human urinary proteins isolated by acetone precipitation or u Kidney Int 62: 1461-9. (2002).

150.0

66. Use of proteomic methods to identify serum biomarkers associated with rat liver toxicity o Clin Chem 51: 1796-803. (2005).

149

67. High-resolution serum proteomic profiling of Alzheimer disease samples reveals disease-spe Clin Chem 51: 1946-54. (2005).

149

68. Standardized approach to proteome profiling of human serum based on magnetic bead separati Clin Chem 51: 973-80. (2005).

149

69. Identification of serum amyloid A as a biomarker to distinguish prostate cancer patients w Clin Chem 51: 695-707. (2005).

149

70. Proteomic profiling of pancreatic cancer for biomarker discovery. Mol Cell Proteomics 4: 523-33. (2005).

149

71. Protein chip array profiling analysis in patients with severe acute respiratory syndrome i Clin Chem 51: 47-55. (2005).

149

72. Serum Proteomic Fingerprints of Adult Patients with Severe Acute Respiratory Syndrome. Clin Chem 0: . (2006).

149

73. Direct-Tissue SELDI-TOF Mass Spectrometry Analysis: A New Application for Clinical Proteom Clin Chem 0: . (2006).

149

74. Reproducibility in Protein Profiling by MALDI-TOF Mass Spectrometry. Clin Chem 0: . (2007).

149

75. Characterization of Diabetic Nephropathy by Urinary Proteomic Analysis: Identification of Clin Chem 0: . (2007).

149

76. Identification of Pro-MMP-7 as a Serum Marker for Renal Cell Carcinoma by Use of Proteomic Clin Chem 0: . (2008).

149

77. Monomeric Calgranulins Measured by SELDI-TOF Mass Spectrometry and Calprotectin Measured b Clin Chem 0: . (2008).

149

78. Putting the "Bio" back into Biomarkers: Orienting Proteomic Discovery toward Biology and a Clin Chem 54: 3-5. (2008).

146

79. Proteomic characterization of nipple aspirate fluid: identification of potential biomarker Breast Cancer Res Treat 80: 87-97. (2003).

142.9

80. High throughput quantitative analysis of serum proteins using glycopeptide capture and liq Mol Cell Proteomics 4: 144-55. (2005).

141

81. Toxicology and genetic toxicology in the new era of "toxicogenomics": impact of "-omics" t Mutat Res 499: 13-25. (2002).

140.7

82. Diagnosis of intra-amniotic infection by proteomic profiling and identification of novel b JAMA 292: 462-9. (2004).

139

83. Global and targeted quantitative proteomics for biomarker discovery. J Chromatogr B Analyt Technol Biomed Life Sci 0: . (2006).

139

84. Higher dimensional (Hi-D) separation strategies dramatically improve the potential for can J Chromatogr B Analyt Technol Biomed Life Sci 0: . (2006).

139

85. Early changes in protein expression detected by mass spectrometry predict tumor response t Cancer Res 64: 9093-100. (2004).

138

86. Rat plasma proteomics: Effects of abundant protein depletion on proteomic analysis. J Chromatogr B Analyt Technol Biomed Life Sci 0: . (2006).

138

87. PARK7 and Nucleoside Diphosphate Kinase A as Plasma Markers for the Early Diagnosis of Str Clin Chem 51: 2043-51. (2005).

134

88. Reducing protein concentration range of biological samples using solid-phase ligand librar J Chromatogr B Analyt Technol Biomed Life Sci 0: . (2006).

134

89. Molecular classification and survival prediction in human gliomas based on proteome analys Cancer Res 64: 2496-501. (2004).

133.3

90. Quantification of C-reactive protein in the serum of patients with rheumatoid arthritis us Proteomics 4: 1175-86. (2004).

133.3

91. Importance of communication between producers and consumers of publicly available experime J Natl Cancer Inst 97: 310-4. (2005).

133

92. Loss of adipocyte-type fatty acid binding protein and other protein biomarkers is associat Cancer Res 56: 4782-90. (1996).

133

93. Discovering Clinical Biomarkers of Ionizing Radiation Exposure with Serum Proteomic Analys Cancer Res 66: 1844-1850. (2006).

133

94. Proteomic analysis reveals field-wide changes in protein expression in the morphologically Cancer Res 66: 6553-62. (2006).

133

95. Identification and validation of differences in protein levels in normal, premalignant, an Cancer Res 66: 11194-206. (2006).

133

96. Proteomics-based identification of proteins secreted in apical surface fluid of squamous m Cancer Res 67: 6565-73. (2007).

133

97. Identification of let-7-regulated oncofetal genes. Cancer Res 68: 2587-91. (2008).

133

98. High-Throughput Quantitative Profiling of Serum N-Glycome by MALDI-TOF Mass Spectrometry a Clin Chem 0: . (2007).

132

99. Enhanced detectability in proteome studies. J Chromatogr B Analyt Technol Biomed Life Sci 0: . (2006).

131

100. Mass spectrometry: uncovering the cancer proteome for diagnostics. Adv Cancer Res 96: 23-50. (2006).

131

101. Proteomic analyses of amniotic fluid: Potential applications in health and diseases. J Chromatogr B Analyt Technol Biomed Life Sci 0: . (2006).

130

102. Proteomics analysis in lung cancer: Challenges and opportunities. Respirology 12: 22-8. (2007).

130

103. An integrated approach to the detection of colorectal cancer utilizing proteomics and bioi World J Gastroenterol 10: 3127-31. (2004).

129

104. Proteomics to display tissue repair opposing injury response to LPS-induced liver injury. World J Gastroenterol 10: 2701-5. (2004).

129

105. Preliminary study on proteomics of gastric carcinoma and its clinical significance. World J Gastroenterol 11: 6249-53. (2005).

129

106. Human blood plasma preparation for two-dimensional gel electrophoresis. J Chromatogr B Analyt Technol Biomed Life Sci 0: . (2006).

129

107. Protein profile of human hepatocarcinoma cell line SMMC-7721: Identification and functiona World J Gastroenterol 13: 2608-14. (2007).

129

108. Moving forward in colorectal cancer research, what proteomics has to tell. World J Gastroenterol 13: 5813-21. (2007).

129

109. Preanalytic Influence of Sample Handling on SELDI-TOF Serum Protein Profiles. Clin Chem 0: . (2007).

128

110. Toxicogenomic approach for assessing toxicant-related disease. Mutat Res 544: 415-24. (2003).

125.0

111. Proteomics to diagnose human tumors and provide prognostic information. Oncology (Williston Park) 18: 521-9; discussi. (2004).

124

112. Proteomic Analysis of Cerebrospinal Fluid Changes Related to Postmortem Interval. Clin Chem 0: . (2006).

124

113. Detection of prostate cancer using serum proteomics pattern in a histologically confirmed J Urol 171: 1782-7. (2004).

123

114. Novel Serum Biomarker Candidates for Liver Fibrosis in Hepatitis C Patients. Clin Chem 0: . (2007).

123

115. Drug sensitivity and resistance genes in cancer chemotherapy: a chemogenomics approach. Drug Discov Today 8: 356-63. (2003).

122.2

116. Gene Expression Profiling of Ovarian Tissues for Determination of Molecular Pathways Refle J Mol Biol 0: . (2006).

122

117. Proteomic analysis of human amniotic fluid. Mol Cell Proteomics 0: . (2007).

122

118. Proteomic mass spectra classification using decision tree based ensemble methods. Bioinformatics 21: 3138-45. (2005).

120

119. Application of the GA/KNN method to SELDI proteomics data. Bioinformatics 20: 1638-40. (2004).

120

120. Finding regions of significance in SELDI measurements for identifying protein biomarkers. Bioinformatics 22: 1515-23. (2006).

120

121. Simultaneous and exact interval estimates for the contrast of two groups based on an extre Bioinformatics 0: . (2007).

120

122. A parsimonious threshold-independent protein feature selection method through the area und Bioinformatics 0: . (2007).

120

123. Identification of diagnostic markers for tuberculosis by proteomic fingerprinting of serum Lancet 368: 1012-21. (2006).

118

124. Proteomic analysis of conditioned media from three breast cancer cell lines: A mine for bi Mol Cell Proteomics 0: . (2007).

117

125. Pharmacoproteomics of a metalloproteinase hydroxamate inhibitor in breast cancer cells: Dy Mol Cell Biol 0: . (2008).

117

126. Finding diagnostic biomarkers in proteomic spectra. Pac Symp Biocomput 0: 279-90. (2006).

115

127. A common phosphotyrosine signature for the Bcr-Abl kinase. Blood 107: 4888-97. (2006).

115

128. Gene and protein expression profiling of human ovarian cancer cells treated with the heat Cancer Res 67: 3239-53. (2007).

115

129. Proteomics analysis of Hodgkin lymphoma: Identification of new players involved in the cro Blood 0: . (2007).

115

130. CCL8 is a potential molecular candidate for the diagnosis of graft versus host disease. Blood 0: . (2008).

115

131. Proteomic profiling of cerebrospinal fluid identifies biomarkers for amyotrophic lateral s J Neurochem 95: 1461-71. (2005).

114

132. Biomarker discovery from pancreatic cancer secretome using a differential proteomics appro Mol Cell Proteomics 0: . (2005).

114

133. Proteomic profiling of cerebrospinal fluid identifies biomarkers for amyotrophic lateral s J Neurochem 0: . (2005).

114

134. Clinical proteomics for cancer biomarker discovery and therapeutic targeting. Technol Cancer Res Treat 1: 263-72. (2002).

113

135. Individual metabolism should guide agriculture toward foods for improved health and nutrit Am J Clin Nutr 74: 283-6. (2001).

111.8

136. Altered expression and localization of creatine kinase B, heterogeneous nuclear ribonucleo Cancer Res 66: 763-9. (2006).

111

137. Proteomics in renal transplantation: opportunities and challenges. Clin Transpl 0: 253-60. (2004).

110

138. Discovering differential protein expression caused by CagA-induced ERK pathway activation World J Gastroenterol 14: 554-62. (2008).

108

139. Apocrine cysts of the breast: Biomarkers, origin, enlargement, and relation with cancer ph Mol Cell Proteomics 0: . (2005).

106

140. Signal maps for mass spectrometry-based comparative proteomics. Mol Cell Proteomics 0: . (2005).

106

141. Comparative proteomic analysis of intra- and interindividual variation in human cerebrospi Mol Cell Proteomics 4: 2000-9. (2005).

106

142. Serum Microarrays for Large Scale Screening of Protein Levels. Mol Cell Proteomics 4: 1942-1947. (2005).

106

143. A Catalogue of Human Saliva Proteins Identified by Free Flow Electrophoresis-based Peptide Mol Cell Proteomics 4: 1826-30. (2005).

106

144. Accelerated discovery of novel protein function in cultured human cells. Mol Cell Proteomics 4: 1319-27. (2005).

106

145. Differential proteomic analysis of bronchoalveolar lavage fluid in asthmatics following se Mol Cell Proteomics 4: 1251-64. (2005).

106

146. An immunoproteomic approach for identification of clinical biomarkers for monitoring disea Mol Cell Proteomics 4: 1052-60. (2005).

106

147. Biomarkers: mining the biofluid proteome. Mol Cell Proteomics 4: 409-18. (2005).

106

148. Analysis of prostate cancer by proteomics using tissue specimens. J Urol 173: 73-8. (2005).

106

149. Biomarkers of congenital obstructive nephropathy: past, present and future. J Urol 172: 852-7. (2004).

106

150. Cancer proteomics: from biomarker discovery to signal pathway profiling. Cancer J 7: 69-78. (0).

106

151. Identification of proteomics signatures of exposure to marine pollutants in mussels (Mytil Mol Cell Proteomics 0: . (2006).

106

152. Mass spectrometric identification of human prostate cancer-derived proteins in serum of xe Mol Cell Proteomics 0: . (2006).

106

153. Identification of PSME3 as a novel serum tumor marker for colorectal cancer by combining t Mol Cell Proteomics 0: . (2006).

106

154. Quantitative comparison of caste differences in honeybee hemolymph. Mol Cell Proteomics 0: . (2006).

106

155. A method for automatically interpreting mass spectra of 18O labeled isotopic clusters. Mol Cell Proteomics 0: . (2006).

106

156. Identification of glioma neovascularisation-related proteins by using MALDI-FTMS and nano- Mol Cell Proteomics 0: . (2007).

106

157. Quantitative proteomic analysis reveals that proteins differentially expressed in chronic Mol Cell Proteomics 0: . (2007).

106

158. High sensitivity detection of plasma proteins by multiple reaction monitoring of N-glycosi Mol Cell Proteomics 0: . (2007).

106

159. A web-based tool for in silico biomarker discovery based on tissue-specific protein profil Mol Cell Proteomics 0: . (2007).

106

160. Biomarkers for Prostate Cancer Detection. J Urol 0: . (2007).

106

161. Urinary proteomic biomarkers in coronary artery disease. Mol Cell Proteomics 0: . (2007).

106

162. Protein profiling of human breast tumor cells identifies novel biomarkers associated with Mol Cell Proteomics 0: . (2008).

106

163. Detection of Bladder Cancer in Human Urine by Metabolomic Profiling Using High Performance J Urol 179: 2422-2426. (2008).

106

164. SELDI-TOF MS profiling of serum for detection of the progression of chronic hepatitis C to Hepatology 41: 634-42. (2005).

105

165. Proteomic profiling of cholangiocarcinoma: Diagnostic potential of SELDI-TOF MS in maligna Hepatology 44: 658-666. (2006).

105

166. Serum protein oxidation and apolipoprotein CIII levels in people with systemic lupus eryth Free Radic Res 0: 1-12. (2007).

105

167. Loss of expression of the adipocyte-type fatty acid-binding protein (A-FABP) is associated Mol Cell Proteomics 4: 570-81. (2005).

103

168. Recursive SVM feature selection and sample classification for mass-spectrometry and microa BMC Bioinformatics 7: 197. (2006).

103

169. CSF biomarker discovery using label-free nano-LC-MS based proteomic profiling: technical a J Sep Sci 30: 214-25. (2007).

103

170. Proteomic approach in the search of new cardiovascular biomarkers. Kidney Int 68: S103-S107. (2005).

102

171. Plasma, urine, and renal expression of adiponectin in human systemic lupus erythematosus. Kidney Int 68: 1825-33. (2005).

102

172. Impact of diabetic nephropathy and angiotensin II receptor blockade on urinary polypeptide Kidney Int 68: 193-205. (2005).

102

173. Biomarker and drug-target discovery using proteomics in a new rat model of sepsis-induced Kidney Int 0: . (2006).

102

174. Enzymes and related proteins as cancer biomarkers: A proteomic approach. Clin Chim Acta 0: . (2007).

102

175. Biomarkers of lupus nephritis determined by serial urine proteomics. Kidney Int 0: . (2008).

102

176. CSF proteome: a protein repository for potential biomarker identification. Expert Rev Proteomics 2: 57-70. (2005).

101

177. Developing a tool for noninvasive monitoring of renal allografts. Expert Rev Proteomics 3: 497-509. (2006).

101

178. TOPP--the OpenMS proteomics pipeline. Bioinformatics 23: e191-7. (2007).

101

179. Use of a Combination of Approaches to Identify and Validate Relevant Tumor-Associated Anti Clin Cancer Res 14: 764-771. (2008).

101

180. New tumor markers: CA125 and beyond. Int J Gynecol Cancer 15: 274-281. (2005).

100

181. Physiological Proteomics: Cells, Organs, Biological Fluids, and Biomarkers. Exp Biol Med (Maywood) 230: 785-786. (2005).

100

182. (1)H/(19)F Magnetic Resonance Molecular Imaging with Perfluorocarbon Nanoparticles. Curr Top Dev Biol 70: 57-76. (2005).

100

183. Is tailored therapy feasible in oncology? Crit Rev Oncol Hematol 0: . (2005).

100

184. Differential proteomic analysis reveals increased cathelicidin expression in porcine bronc Vet Res 37: 75-87. (0).

100

185. [Contribution of proteomic analysis to study cardiovascular physiopathology.] Ann Biol Clin (Paris) 63: 611-7. (0).

100

186. Critical care: applying genomics to inflammation outcomes. Environ Health Perspect 113: a816-21. (2005).

100

187. A proteomic analysis of mammalian preimplantation embryonic development. Reproduction 130: 899-905. (2005).

100

188. [Screening hepatocellular carcinoma autoantibodies by serological proteome analysis.] Zhonghua Gan Zang Bing Za Zhi 13: 832-5. (2005).

100

189. SELDI-MS-based expression profiling of ductal invasive and lobular invasive human breast c Pathol Res Pract 201: 763-70. (2005).

100

190. How proteomics reveals potential biomarkers in brain diseases. Expert Rev Proteomics 2: 901-13. (2005).

100

191. Biomarker discovery using protein microarray technology platforms: antibody-antigen comple Expert Rev Proteomics 2: 879-89. (2005).

100

192. Bioinformatics approaches in clinical proteomics. Expert Rev Proteomics 2: 847-62. (2005).

100

193. Biomarkers for neurodegenerative diseases. Curr Opin Neurol 18: 698-705. (2005).

100

194. Chronic inflammation and breast pathology: a theoretical model. Biol Res Nurs 7: 118-29. (2005).

100

195. Expression profiling in the aging brain: A perspective. Ageing Res Rev 4: 529-47. (2005).

100

196. Genomic epidemiology cohorts in Korea: present and the future. Asian Pac J Cancer Prev 6: 238-43. (0).

100

197. Towards the application of proteomics in renal disease diagnosis. Clin Sci (Lond) 109: 421-30. (2005).

100

198. Pancreatic cancer proteome: the proteins that underlie invasion, metastasis, and immunolog Gastroenterology 129: 1187-97. (2005).

100

199. Using proteomic approaches to identify new biomarkers for detection and monitoring of ovar Gynecol Oncol 0: . (2005).

100

200. [Molecular diagnostics of ovarian cancer using proteome techniques] Biomed Khim 51: 367-83. (0).

100

201. Protein Detection in Dried Blood by Surface-Enhanced Laser Desorption/Ionization-Time of F Biol Neonate 89: 126-132. (2005).

100

202. Online coupling of capillary electrophoresis with mass spectrometry for the identification Expert Rev Proteomics 2: 639-47. (2005).

100

203. [Proteomic profiling: the potential of Seldi-Tof for the identification of new cancer biom Bull Cancer 92: 763-8. (2005).

100

204. Proteomics in rheumatology: a new direction for old diseases. Semin Arthritis Rheum 35: 67-76. (2005).

100

205. [The application of surface-enhanced laser desorption/inionation-time of flight-mass spect Zhonghua Nei Ke Za Zhi 44: 573-6. (2005).

100

206. Biochemical and molecular markers in renal cell carcinoma: an update and future prospects. Biomarkers 10: 258-94. (0).

100

207. Proteomic Patterns of Preinvasive Bronchial Lesions. Am J Respir Crit Care Med 172: 1556-1562. (2005).

100

208. Proteomics in nutrition research: principles, technologies and applications. Br J Nutr 94: 302-14. (2005).

100

209. Proteomic analysis of sputum from adults and children with cystic fibrosis and from contro Am J Respir Crit Care Med 172: 1416-26. (2005).

100

210. Discriminatory proteomic biomarker analysis identifies free hemoglobin in the cerebrospina Am J Obstet Gynecol 193: 957-64. (2005).

100

211. CSF biomarkers for Alzheimer's disease: use in early diagnosis and evaluation of drug trea iagn 5: 661-72. (2005).

100

212. Serum proteomics study of the squamous cell carcinoma antigen 1 in tongue cancer. Oral Oncol 0: . (2005).

100

213. Identification of oxidative stress-related proteins for predictive screening of hepatotoxi J Toxicol Sci 30: 213-27. (2005).

100

214. Gefitinib-responsive EGFR-positive colorectal cancers have different proteome profiles fro Eur J Cancer 41: 2338-46. (2005).

100

215. [Clinical proteomics: towards early detection of cancers] Med Sci (Paris) 21: 722-9. (0).

100

216. Effects of corticosteroids on noninvasive biomarkers of inflammation in asthma and chronic Proc Am Thorac Soc 1: 191-9. (2004).

100

217. Proteomic analysis of differently expressed proteins in a mouse model for allergic asthma. J Korean Med Sci 20: 579-85. (2005).

100

218. Proteomic identification of biomarkers of traumatic brain injury. Expert Rev Proteomics 2: 603-14. (2005).

100

219. Building the mitochondrial proteome. Expert Rev Proteomics 2: 541-51. (2005).

100

220. Biology and therapy of mantle cell lymphoma. Curr Opin Oncol 17: 425-31. (2005).

100

221. SELDI-TOF-MS: the proteomics and bioinformatics approaches in the diagnosis of breast canc Breast 14: 250-5. (2005).

100

222. Tailored therapy of colorectal cancer: results, challenges and future directions. Cancer J 11: 175-88. (0).

100

223. Serum proteomic fingerprinting discriminates between clinical stages and predicts disease J Clin Oncol 23: 5088-93. (2005).

100

224. Application of emerging technologies in toxicology and safety assessment: regulatory persp Int J Toxicol 24: 153-5. (0).

100

225. Applications of emerging technologies in toxicology and safety assessment. Int J Toxicol 24: 135-7. (0).

100

226. Influence of hormone replacement therapy on proteomic pattern in serum of postmenopausal w Maturitas 51: 334-42. (2005).

100

227. A proteomics analysis of cellular proteins associated with HBV genotype-specific HBX: pote J Clin Virol 33: 293-8. (2005).

100

228. [Identification of biomarkers in serum of early rheumatoid arthritis by proteomic methods] Zhonghua Yi Xue Za Zhi 85: 1261-5. (2005).

100

229. Application of serum SELDI proteomic patterns in diagnosis of lung cancer. BMC Cancer 5: 83. (2005).

100

230. Protein fingerprints of anti-cancer effects of cyclin-dependent kinase inhibition: identif Technol Cancer Res Treat 4: 447-54. (2005).

100

231. Characterization of the secreted proteome of rat hepatocytes cultured in collagen sandwich Chem Res Toxicol 18: 1132-9. (2005).

100

232. Comparison of the specificity and sensitivity of traditional methods for assessment of nep J Appl Toxicol 25: 277-95. (0).

100

233. Proteomic but not enzyme-linked immunosorbent assay technology detects amniotic fluid mono Clin Diagn Lab Immunol 12: 837-44. (2005).

100

234. The Oral Fluid MEMS/NEMS Chip (OFMNC): diagnostic and translational applications. Adv Dent Res 18: 3-5. (2005).

100

235. Rarity gives a charm: evaluation of trace proteins in plasma and serum. Expert Rev Proteomics 2: 393-406. (2005).

100

236. Proteomic analysis of renal diseases: unraveling the pathophysiology and biomarker discove Expert Rev Proteomics 2: 349-66. (2005).

100

237. The use of soluble, salivary c-erbB-2 for the detection and post-operative follow-up of br Adv Dent Res 18: 17-24. (2005).

100

238. The emergence of genomic and proteomic biomarkers in heart transplantation. J Heart Lung Transplant 24: S213-8. (2005).

100

239. How can toxicogenomics inform risk assessment? Toxicol Appl Pharmacol 207: 592-8. (2005).

100

240. Serum protein profile in systemic-onset juvenile idiopathic arthritis differentiates respo Arthritis Res Ther 7: R746-55. (2005).

100

241. Bioinformatics in microbial biotechnology--a mini review. Microb Cell Fact 4: 19. (2005).

100

242. Molecular biomarkers for the study of childhood leukemia. Toxicol Appl Pharmacol 206: 237-45. (2005).

100

243. Biomarkers of cadmium and arsenic interactions. Toxicol Appl Pharmacol 206: 191-7. (2005).

100

244. Metabolomic and proteomic biomarkers for III-V semiconductors: chemical-specific porphyrin Toxicol Appl Pharmacol 206: 121-30. (2005).

100

245. Enrichment of low-molecular-weight proteins from biofluids for biomarker discovery. Expert Rev Proteomics 2: 139-45. (2005).

100

246. Isotope-differentiated binding energy shift tags (IDBEST) for improved targeted biomarker Expert Rev Proteomics 1: 421-31. (2004).

100

247. All about DIGE: quantification technology for differential-display 2D-gel proteomics. Expert Rev Proteomics 1: 401-9. (2004).

100

248. Large-scale proteomic analysis of membrane proteins. Expert Rev Proteomics 1: 293-302. (2004).

100

249. Integrated analysis of genetic, genomic and proteomic data. Expert Rev Proteomics 1: 67-75. (2004).

100

250. Target class strategies in mass spectrometry-based proteomics. Expert Rev Proteomics 1: 57-66. (2004).

100

251. A two-dimensional electrophoresis preliminary approach to human hepatocarcinoma differenti J Cell Mol Med 9: 462-7. (0).

100

252. Early prediction of acute renal injury using urinary proteomics. Am J Nephrol 25: 318-26. (0).

100

253. Low molecular weight proteomic information distinguishes metastatic from benign pheochromo Endocr Relat Cancer 12: 263-72. (2005).

100

254. Studies on substantially increased proteins in follicular fluid of bovine ovarian follicul Reprod Biol Endocrinol 3: 23. (2005).

100

255. Rapid discovery of putative protein biomarkers of traumatic brain injury by SDS-PAGE-capil J Neurotrauma 22: 629-44. (2005).

100

256. Use of 'Omic' technologies to study humans exposed to benzene. Chem Biol Interact 153: 123-7. (2005).

100

257. Protein expression analysis of rat testes induced testicular toxicity with several reprodu J Toxicol Sci 30: 111-26. (2005).

100

258. An emerging role for comprehensive proteome analysis in human pregnancy research. Reproduction 129: 685-96. (2005).

100

259. Data input module for Birth Defects Systems Manager. Reprod Toxicol 20: 369-75. (0).

100

260. Laboratory diagnosis of acute myocardial injury. Cardiovasc Pathol 14: 156-61. (0).

100

261. Disease proteomics toward bedside reality. J Gastroenterol 40: 7-13. (2005).

100

262. Simultaneous measurement of multiple radiation-induced protein expression profiles using t Adv Space Res 34: 1362-7. (2004).

100

263. Biomarkers for the detection and prognosis of prostate cancer. Curr Urol Rep 6: 171-6. (2005).

100

264. Quantitative proteomics of cerebrospinal fluid from patients with Alzheimer disease. J Alzheimers Dis 7: 125-33; discuss. (2005).

100

265. Global approach to perinatal medicine: functional genomics and proteomics. J Perinat Med 33: 5-16. (2005).

100

266. [Proteomics and diagnostic application] Rinsho Byori 53: 239-45. (2005).

100

267. The molecular make-up of a tumour: proteomics in cancer research. Clin Sci (Lond) 108: 369-83. (2005).

100

268. Biomarkers in psychotropic drug development: integration of data across multiple domains. Annu Rev Pharmacol Toxicol 45: 227-46. (2005).

100

269. Comparative evaluation of two two-dimensional gel electrophoresis image analysis software J Orthop Sci 10: 160-6. (2005).

100

270. Proteomics in prostate cancer. Curr Opin Urol 15: 151-6. (2005).

100

271. Analysis of cerebellum proteomics in the hydrocephalic H-Tx rat. Neuroreport 16: 571-4. (2005).

100

272. Progression of head and neck squamous cell cancer. Cancer Metastasis Rev 24: 107-27. (2005).

100

273. A distinctive molecular signature of multiple sclerosis derived from MALDI-TOF/MS and seru J Mol Neurosci 25: 119-25. (2005).

100

274. Biomarker profiling of plasma from acute coronary syndrome patients. Application of Protei Int Angiol 23: 246-54. (2004).

100

275. Proteomic applications of surface plasmon resonance biosensors: analysis of protein arrays Exp Mol Med 37: 1-10. (2005).

100

276. Overview of molecular, cellular, and genetic neurotoxicology. Neurol Clin 23: 307-20. (2005).

100

277. Profiling of nuclear extract proteins from human neuroblastoma cell lines: the search for J Pediatr Surg 40: 349-58. (2005).

100

278. Molecular diagnosis of solid and cystic lesions of the pancreas. Clin Lab Med 25: 101-16. (2005).

100

279. New science-based endpoints to accelerate oncology drug development. Eur J Cancer 41: 491-501. (2005).

100

280. Workshop on cancer biometrics: identifying biomarkers and surrogates of cancer in patients J Immunother 28: 79-119. (0).

100

281. Biomarkers for melanoma. Curr Opin Oncol 17: 167-71. (2005).

100

282. Biomarker discovery in biological fluids. Methods 35: 291-302. (2005).

100

283. Biomarkers of Alzheimer disease in plasma. NeuroRx 1: 226-34. (2004).

100

284. Genetic factors in preterm birth--the future. BJOG 112: 97-102. (2005).

100

285. [New biomarkers for prostate cancer] Nippon Rinsho 63: 351-9. (2005).

100

286. Biomarkers in inflammatory bowel disease. Curr Opin Gastroenterol 20: 318-27. (2004).

100

287. Proteome-wide analysis of head and neck squamous cell carcinomas using laser-capture micro Oral Oncol 41: 183-99. (2005).

100

288. [Discovery of disease biomarkers by ProteinChip system; clinical proteomics as noninvasive Rinsho Byori 52: 973-9. (2004).

100

289. Translational neurochemical research in acute human brain injury: the current status and p J Neurotrauma 22: 3-41. (2005).

100

290. Proteomic patterns: their potential for disease diagnosis. Mol Cell Endocrinol 230: 95-106. (2005).

100

291. Proteomic biomarker analysis of amniotic fluid for identification of intra-amniotic inflam BJOG 112: 173-81. (2005).

100

292. Genomic and proteomic profiling for biomarkers and signature profiles of toxicity. Curr Opin Mol Ther 6: 600-7. (2004).

100

293. Upregulated expression of human neutrophil peptides 1, 2 and 3 (HNP 1-3) in colon cancer s BMC Cancer 5: 8. (2005).

100

294. Mechanistic data and cancer risk assessment: the need for quantitative molecular endpoints Environ Mol Mutagen 45: 214-21. (0).

100

295. [Diagnostic application of serum protein pattern and artificial neural network software in Ai Zheng 24: 67-71. (2005).

100

296. Treatment and control of human African trypanosomiasis. Curr Opin Infect Dis 17: 565-71. (2004).

100

297. Molecular markers and prostate cancer prognosis. Clin Prostate Cancer 3: 157-64. (2004).

100

298. High-throughput screening of novel peptide inhibitors of an integrin receptor from the hex J Biomol Screen 9: 687-94. (2004).

100

299. Candidate-based proteomics in the search for biomarkers of cardiovascular disease. J Physiol 563: 23-60. (2005).

100

300. The proteomic approach to urological biomarkers. BJU Int 94: 1215-6. (2004).

100

301. Biomarker investigations from the ATAC trial: the role of TA01. Breast Cancer Res Treat 87: S11-8. (2004).

100

302. Estrogen and progesterone receptor isoforms: clinical significance in breast cancer. Breast Cancer Res Treat 87: S3-10. (2004).

100

303. Proteomic analysis of voided urine after prostatic massage from patients with prostate can Urology 64: 1238-43. (2004).

100

304. Use of mass spectrometry to identify protein biomarkers of disease severity in the synovia Arthritis Rheum 50: 3792-803. (2004).

100.0

305. Application of proteomics and protein analysis for biomarker and target finding for immuno Methods Mol Med 109: 155-74. (2005).

100

306. Genomic and proteomic approaches for probing the role of vitamin D in health. Am J Clin Nutr 80: 1730S-4S. (2004).

100.0

307. [New effect biomarkers] G Ital Med Lav Ergon 26: 302-10. (0).

100

308. Microarray analysis of activated mixed glial (microglia) and monocyte-derived macrophage g J Neuroimmunol 157: 27-38. (2004).

100

309. [Proteome analysis for identification of tumor-associated biomarkers in breast cancer] Ai Zheng 23: 1577-81. (2004).

100

310. Protein biomarkers for breast cancer prevention. Eur J Cancer Prev 13: 307-17. (2004).

100

311. Proteomic fingerprints for potential application to early diagnosis of severe acute respir Clin Chem 51: 56-64. (2005).

100.0

312. Diagnosis of pancreatic cancer using serum proteomic profiling. Neoplasia 6: 674-86. (0).

100

313. Evidence-based medical perspectives: the evolving role of PSA for early detection, monitor Am J Ther 11: 501-6. (0).

100

314. Identification of differentially expressed proteins in pancreatic cancer using a global pr Methods Mol Med 103: 189-97. (2005).

100

315. Therapeutic targeting of prostate cancer. Cancer Biol Ther 3: 1028-30. (2004).

100

316. Molecular diagnosis of solid and cystic lesions of the pancreas. Gastroenterol Clin North Am 33: 891-906. (2004).

100

317. Discovery of laryngeal carcinoma by serum proteomic pattern analysis. Sci China C Life Sci 47: 219-23. (2004).

100

318. Proteomics in platelet science. Curr Hematol Rep 3: 462-9. (2004).

100

319. Proteomics in cancer screening and management in gynecologic cancer. Curr Oncol Rep 6: 456-62. (2004).

100

320. Biomarkers for risk assessment in molecular epidemiology of cancer. Technol Cancer Res Treat 3: 505-14. (2004).

100

321. On the technicalities of discovering and applying protein biomarkers for cancer prevention Eur J Cancer Prev 13: 437-46. (2004).

100

322. Methods for enhancing the efficiency of dental/oral health clinical trials: current status J Dent Res 83: 744-50. (2004).

100

323. Combination of 'omics' data to investigate the mechanism(s) of hydrazine-induced hepatotox Biomarkers 9: 116-38. (0).

100

324. Genotypic and phenotypic biomarker profiles for individual risk assessment and cancer dete Front Biosci 9: 2671-9. (2004).

100

325. Identification of tumor-associated plasma biomarkers using proteomic techniques: from mous Proteomics 4: 2766-75. (2004).

100.0

326. Profiling of rat plasma by surface-enhanced laser desorption/ionization time-of-flight mas J Chromatogr A 1043: 65-71. (2004).

100

327. [Screening urine markers of renal cell carcinoma using SELDI-TOF-MS] Zhonghua Yi Xue Za Zhi 84: 1092-5. (2004).

100

328. Proteomics in pathology research. Lab Invest 84: 1227-44. (2004).

100.0

329. Chemoprevention of melanoma. Curr Oncol Rep 6: 406-13. (2004).

100

330. Biomarker discovery and validation: technologies and integrative approaches. Trends Biotechnol 22: 411-6. (2004).

100.0

331. ProteinChip Array analysis of microdissected colorectal carcinoma and associated tumor str Anticancer Res 24: 1791-6. (0).

100

332. Proteomics of buccal squamous cell carcinoma: the involvement of multiple pathways in tumo Proteomics 4: 2465-75. (2004).

100.0

333. [Molecular-target drug] Gan To Kagaku Ryoho 31: 1034-40. (2004).

100

334. [Biomarkers in breast cancer] Gan To Kagaku Ryoho 31: 1021-6. (2004).

100

335. [Biomarker in gynecologic malignancies] Gan To Kagaku Ryoho 31: 1003-7. (2004).

100

336. Discrimination models using variance-stabilizing transformation of metabolomic NMR data. OMICS 8: 118-30. (2004).

100

337. Proteomics in pathology, research and practice. Pathol Res Pract 200: 69-82. (2004).

100

338. Frontiers in nutrigenomics, proteomics, metabolomics and cancer prevention. Mutat Res 551: 51-64. (2004).

100.0

339. Recent developments in biomarkers for the early detection of lung cancer: perspectives bas Curr Opin Pulm Med 10: 242-7. (2004).

100

340. A technical triade for proteomic identification and characterization of cancer biomarkers. Cancer Res 64: 4099-104. (2004).

100.0

341. Nasal lavage fluid and proteomics as means to identify the effects of the irritating epoxy Biomarkers 9: 56-70. (0).

100

342. Haptoglobin alpha-subunit and hepatocyte growth factor can potentially serve as serum tumo Anticancer Res 24: 1031-8. (0).

100

343. Analysis of molecular aberrations in ovarian cancer allows novel target identification. J Obstet Gynaecol Can 26: 461-74. (2004).

100

344. A proteomic investigation of drug-induced steatosis in rat liver. Chem Res Toxicol 17: 605-12. (2004).

100

345. Identification of in vitro protein biomarkers of idiosyncratic liver toxicity. Toxicol In Vitro 18: 533-41. (2004).

100

346. The future of proteomics in the study of alcoholism. Alcohol Clin Exp Res 28: 228-32. (2004).

100

347. High-throughput proteomics for alcohol research. Alcohol Clin Exp Res 28: 203-10. (2004).

100

348. Serum protein profiling by SELDI mass spectrometry: detection of multiple variants of seru Lab Invest 84: 845-56. (2004).

100.0

349. Surface-enhanced laser desorption/ionization-time of flight-mass spectrometry (SELDI-TOF-M J Clin Lab Anal 18: 170-5. (2004).

100

350. [Toxicoproteomics: first experiences in a BMBF-study] ALTEX 21: 28-40. (2004).

100

351. Proteomics for nasal secretion analysis. Curr Allergy Asthma Rep 4: 224-9. (2004).

100

352. Emerging biomarker technologies. IARC Sci Publ 0: 437-50. (2004).

100

353. [Micro-array based technologies to study the proteome: technological progress and applicat Ann Biol Clin (Paris) 62: 139-48. (0).

100

354. Population screening for prostate cancer and emerging concepts for young men. Clin Prostate Cancer 2: 87-97. (2003).

100

355. Molecular profiling approaches for identifying novel biomarkers. Expert Opin Drug Saf 3: 137-51. (2004).

100

356. [Advances in cancer proteomics study] Ai Zheng 23: 113-7. (2004).

100

357. Identification by proteomic analysis of calreticulin as a marker for bladder cancer and ev Clin Chem 50: 857-66. (2004).

100.0

358. Functional relationship and gene ontology classification of breast cancer biomarkers. Int J Biol Markers 18: 241-72. (0).

100

359. Surrogate tissue analysis: monitoring toxicant exposure and health status of inaccessible Toxicol Appl Pharmacol 194: 189-99. (2004).

100

360. Identification of tumor-associated proteins in oral tongue squamous cell carcinoma by prot Proteomics 4: 271-8. (2004).

100.0

361. Post-genomic applications of tissue microarrays: basic research, prognostic oncology, clin Histol Histopathol 19: 325-35. (2004).

100

362. Diet, nutrition, and cancer prevention: the postgenomic era. J Nutr 133: 3830S-3836S. (2003).

100.0

363. Cardiovascular genomics. Cardiovasc Pathol 12: 249-54. (0).

100

364. High-throughput proteomics and protein biomarker discovery in an experimental model of inf Drugs 63: 23-9. (2003).

100

365. Biomarkers, validation and pharmacokinetic-pharmacodynamic modelling. Clin Pharmacokinet 42: 997-1022. (2003).

100

366. [Application of proteomic approach for solid tumor marker discovery] Ai Zheng 22: 664-7. (2003).

100

367. Reaction of detoxification mechanisms in suspension cultured spruce cells (Picea abies L. Environ Sci Pollut Res Int 10: 225-34. (2003).

100

368. Toxicoproteomics: a parallel approach to identifying biomarkers. Environ Health Perspect 111: A578-9. (2003).

100

369. A data-analytic strategy for protein biomarker discovery: profiling of high-dimensional pr Biostatistics 4: 449-63. (2003).

100

370. What is the relevance of bioinformatics to pharmacology? Trends Pharmacol Sci 24: 434-9. (2003).

100

371. Proteomic approaches to the diagnosis, treatment, and monitoring of cancer. Adv Exp Med Biol 532: 59-68. (2003).

100

372. [Progress in human disease proteomics] Zhongguo Yi Xue Ke Xue Yuan Xue Bao 24: 219-22. (2002).

100

373. Molecular markers of endocrine disruption in aquatic organisms. J Toxicol Environ Health B Crit Rev 6: 453-96. (0).

100

374. A stochastic model for optimizing composite predictors based on gene expression profiles. Pharm Res 20: 996-1000. (2003).

100

375. Clinical biomarkers in drug discovery and development. Nat Rev Drug Discov 2: 566-80. (2003).

100

376. Proteomics as a tool for detection of nuclear matrix proteins and new biomarkers for scree Anticancer Res 23: 805-12. (0).

100

377. Selecting differentially expressed genes from microarray experiments. Biometrics 59: 133-42. (2003).

100

378. A strategy for the comparative analysis of serum proteomes for the discovery of biomarkers Proteomics 3: 601-9. (2003).

100.0

379. Biomarkers in drug discovery and development: from target identification through drug mark J Clin Pharmacol 43: 329-41. (2003).

100

380. Circulating tumor cells and serum tumor biomarkers in small cell lung cancer. Anticancer Res 23: 49-62. (0).

100

381. Proteomics for monitoring immune responses to cancer vaccines. Curr Opin Mol Ther 5: 39-43. (2003).

100

382. Validating biomarkers: early detection research network launches first phase III study. J Natl Cancer Inst 95: 422-3. (2003).

100

383. [Toxicogenomics--a new paradigm of toxicology and birth of reverse toxicology] Kokuritsu Iyakuhin Shokuhin Eisei Kenkyusho Hokoku 0: 39-52. (2002).

100

384. SELDI ProteinChip array in oncoproteomic research. Technol Cancer Res Treat 1: 273-80. (2002).

100

385. Genomic biomarkers of toxicity. Curr Opin Drug Discov Devel 6: 41-9. (2003).

100

386. Reliability of tissue microarrays in detecting protein expression and gene amplification i Mod Pathol 16: 79-84. (2003).

100.0

387. NMR-based metabolomics. Drug Chem Toxicol 25: 375-82. (2002).

100

388. Peptidomic approaches in proteomic research. Curr Opin Mol Ther 4: 236-41. (2002).

100

389. Fully automated proteomic detection of cervical dysplasia. Anal Quant Cytol Histol 24: 137-46. (2002).

100

390. Biomarkers, yesterday, today and tomorrow: the basis for health claims. Asia Pac J Clin Nutr 11: S87-9. (2002).

100

391. Functional food ingredients against colorectal cancer. An example project integrating func Nutr Metab Cardiovasc Dis 11: 94-8. (2001).

100

392. From cDNA microarrays to high-throughput proteomics. Implications in the search for preven Restor Neurol Neurosci 18: 137-42. (2001).

100

393. Proteomics in the post-genome age. Biopolymers 60: 206-11. (2001).

100

394. Proteomic strategies for biomarker identification: progress and challenges. Curr Opin Mol Ther 2: 643-50. (2000).

100

395. Molecular alterations in bladder cancer. Urol Res 26: 223-33. (1998).

100

396. Plasma proteins as early biomarkers of exposure to carcinogenic aromatic amines. Chem Biol Interact 93: 221-34. (1994).

100

397. The use of quantitative two-dimensional gel electrophoresis to analyze changes in alveolar Am J Respir Cell Mol Biol 2: 281-8. (1990).

100

398. SELDI-TOF proteomic analysis and cancer detection. Surgeon 3: 383-90, 422. (2005).

100

399. The quest for brain disorder biomarkers(*). J Med Invest 52: 231-5. (2005).

100

400. Application of surface-enhanced laser desorption/ionization time-of-flight-based serum pro Asian J Androl 8: 45-51. (2006).

100

401. Proteomic Profiling in the Sera of Workers Occupationally Exposed to Arsenic and Lead: Ide Biometals 18: 603-613. (2005).

100

402. Proteomic Identification of Lower Apolipoprotein A-I in Alzheimer's Disease. Dement Geriatr Cogn Disord 21: 155-161. (2006).

100

403. [Proteomic analysis of prostate cancer using surface enhanced laser desorption/ionization Zhonghua Yi Xue Za Zhi 85: 3172-5. (2005).

100

404. Biomarker discovery for ovarian cancer using SELDI-TOF-MS. Gynecol Oncol 0: . (2006).

100

405. Proteomic analysis of individual human embryos to identify novel biomarkers of development Fertil Steril 85: 101-7. (2006).

100

406. Proteomic research in renal transplantation. Ther Drug Monit 28: 19-22. (2006).

100

407. Proteomic profiling of mature CD10+ B-cell lymphomas. Am J Clin Pathol 124: 920-9. (2005).

100

408. Neural network-based analysis of thiol proteomics data in identifying potential selenium t Prep Biochem Biotechnol 36: 37-64. (2006).

100

409. An approach to the validation of biomarkers of harm for use in a tobacco context. Regul Toxicol Pharmacol 0: . (2006).

100

410. Proteomic Evaluation of Neonatal Exposure to 2,2 ,4,4 ,5-Pentabromodiphenyl Ether. Environ Health Perspect 114: 254-259. (0).

100

411. Development of biosensors for cancer clinical testing. Biosens Bioelectron 0: . (2006).

100

412. Proteomic strategies and their application in cancer research. Tumori 91: 447-55. (0).

100

413. Value of proteomics applied to the follow-up in stem cell transplantation. Ann Hematol 0: 1-7. (2006).

100

414. Application of proteomics in cardiovascular medicine. Int J Cardiol 0: . (2006).

100

415. Proteomic analysis of rat plasma by two-dimensional liquid chromatography and matrix-assis J Chromatogr A 0: . (2006).

100

416. Pharmacogenomics and clinical biomarkers in drug discovery and development. Am J Clin Pathol 124: S29-41. (2005).

100

417. Identification of potential CSF biomarkers in ALS. Neurology 0: . (2006).

100

418. [Proteomics technology for screening biomarkers of oligospermic candidates] Zhonghua Nan Ke Xue 12: 39-42. (2006).

100

419. Central Nervous System Drug Development: An Integrative Biomarker Approach toward Individu NeuroRx 2: 683-95. (2005).

100

420. Serum proteomic patterns associated with sleep-disordered breathing in children. Pediatr Res 59: 466-70. (2006).

100

421. [Identification of biomarkers and therapeutic targets for renal cell cancer using ProteinC Urologe A 0: . (2006).

100

422. Heparin cofactor II-thrombin complex in MPS I: A biomarker of MPS disease. Mol Genet Metab 0: . (2006).

100

423. Discovery and validation of new protein biomarkers for urothelial cancer: a prospective an Lancet Oncol 7: 230-40. (2006).

100

424. Identification of members of the annexin family in the detergent-insoluble fraction of rat J Chromatogr A 0: . (2006).

100

425. Plasma proteomic pattern as biomarkers for ovarian cancer. Int J Gynecol Cancer 16: 139-46. (0).

100

426. Identification of parotid salivary biomarkers in Sjogren's syndrome by surface-enhanced la Rheumatology (Oxford) 0: . (2006).

100

427. Defining aggressive prostate cancer using a 12-gene model. Neoplasia 8: 59-68. (2006).

100

428. The molecular diagnosis of hepatitis B virus-associated hepatocellular carcinoma. Crit Rev Clin Lab Sci 43: 69-101. (2006).

100

429. Proteomic Profiling of Urinary Protein Excretion in the Factor H-Deficient Mouse. Am J Nephrol 26: 127-135. (2006).

100

430. Identification of protein biomarkers for schizophrenia and bipolar disorder in the postmor Neurobiol Dis 0: . (2006).

100

431. Technologies to shape the future: proteomics applications in anesthesiology and critical c Anesth Analg 102: 1207-16. (2006).

100

432. Biomarkers for Alzheimer's disease - Clinical needs and application. J Alzheimers Dis 8: 339-46. (2005).

100

433. Cancer biomarkers: knowing the present and predicting the future. Fut Oncol 1: 37-50. (2005).

100

434. Proteomic profiling of human urine using multi-dimensional protein identification technolo J Chromatogr A 1111: 166-74. (2006).

100

435. Present Status of Clinical Proteomic Analysis for the Early Detection and Determination of Ann Thorac Cardiovasc Surg 12: 4-9. (2006).

100

436. APO-AII IS AN ELEVATED BIOMARKER OF CHRONIC NON-HUMAN PRIMATE ETHANOL SELF-ADMINISTRATION. Alcohol Alcohol 0: . (2006).

100

437. Plasma proteomic profiling: Search for lung cancer diagnostic and early detection markers. Oncol Rep 15: 1367-72. (2006).

100

438. A Systems Approach to Clinical Oncology: Focus on Breast Cancer. Proteome Sci 4: 5. (2006).

100

439. Clinical proteomics: searching for better tumour markers with SELDI-TOF mass spectrometry. Trends Pharmacol Sci 0: . (2006).

100

440. Proteomic dissection of DNA polymerization. Expert Rev Proteomics 3: 197-211. (2006).

100

441. Proteomic technology for biomarker profiling in cancer: an update. J Zhejiang Univ Sci B 7: 411-20. (2006).

100

442. Recommendations of the National Heart, Lung, and Blood Institute Working Group on Cerebrov Stroke 0: . (2006).

100

443. Proteomic analysis of differential protein expression in early process of pancreatic regen Acta Pharmacol Sin 27: 568-578. (2006).

100

444. Proteomics: Recent Applications and New Technologies. Basic Clin Pharmacol Toxicol 98: 432-441. (2006).

100

445. Optimization and evaluation of surface-enhanced laser-desorption/ionization time-of-flight Proteome Sci 4: 7. (2006).

100

446. Acute toxicity profile of cadmium revealed by proteomics in brain tissue of Paralichthys o Aquat Toxicol 0: . (2006).

100

447. Following the differentiation of human pluripotent stem cells by proteomic identification Stem Cells Dev 15: 221-31. (2006).

100

448. Proteomics for the identification of new prostate cancer biomarkers. Urol Oncol 24: 231-6. (0).

100

449. Proteomic analysis of suction blister fluid isolated from human skin. Clin Exp Dermatol 31: 445-8. (2006).

100

450. [Serum proteomic profiles of the subjects with esophageal precancerous and cancerous lesio Ai Zheng 25: 549-54. (2006).

100

451. [Tissue banks for molecular diagnostics] Ther Umsch 63: 267-71. (2006).

100

452. Diagnosis of Gastric Cancer by Serum Proteomic Fingerprinting. Gastroenterology 130: 1858-1864. (2006).

100

453. Emerging therapeutic targets in multiple sclerosis. Curr Opin Neurol 19: 260-266. (2006).

100

454. Modeling the brain-pituitary-gonad axis in salmon. Mar Environ Res 0: . (2006).

100

455. [Identification of biomarkers in the serum of the patients with poorly differentiated gast Zhonghua Wei Chang Wai Ke Za Zhi 9: 253-6. (2006).

100

456. [Clinical proteomics in laboratory medicine] Rinsho Byori 54: 413-20. (2006).

100

457. Lipid mediator informatics and proteomics in inflammation-resolution. ScientificWorldJournal 6: 589-614. (2006).

100

458. Identification of serum biomarkers for colon cancer by proteomic analysis. Br J Cancer 0: . (2006).

100

459. Proteomics: applications to the study of rheumatoid arthritis and osteoarthritis. J Am Acad Orthop Surg 14: 325-32. (2006).

100

460. Proteomic analysis of differential protein expression in atherosclerosis. Biomarkers 11: 279-90. (0).

100

461. [Determination of differentially expressed proteins and it's significance among chronic si Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi 41: 171-5. (2006).

100

462. Synovial biomarkers in the spondylarthropathies. Curr Opin Rheumatol 18: 359-363. (2006).

100

463. Application of a suite of biomarkers in Posidonia oceanica (L.) delile to assess the ecoto Mar Environ Res 0: . (2006).

100

464. Proteomics approaches to urologic diseases. Expert Rev Proteomics 3: 283-96. (2006).

100

465. Quantitative and qualitative differences in protein expression between papillary thyroid c Mol Carcinog 0: . (2006).

100

466. The role of mass spectrometry in biomarker discovery and measurement. Curr Drug Metab 7: 525-39. (2006).

100

467. Altered expression of serum protein in ginsenoside Re-treated diabetic rats detected by SE J Ethnopharmacol 0: . (2006).

100

468. Proteomic analysis identifies alterations in cellular morphology and cell death pathways i Brain Res 0: . (2006).

100

469. Serum proteomic features for detection of endometrial cancer. Int J Gynecol Cancer 16: 1374-8. (0).

100

470. Molecular prognostic markers in resectable colorectal liver metastases: A systematic revie Eur J Cancer 0: . (2006).

100

471. Biomarkers in acute cardiac disease: the present and the future. J Am Coll Cardiol 48: 1-11. (2006).

100

472. Molecular determinants of differential sensitivity to docetaxel and paclitaxel in human pe Anticancer Res 26: 1983-8. (0).

100

473. Comparison of different separation technologies for proteome analyses: Isoform resolution J Chromatogr A 0: . (2006).

100

474. Plasma proteome analysis reveals the geographical origin and liver tumor status of Dab (Li Environ Sci Technol 40: 4031-6. (2006).

100

475. [Preliminary study of serum proteome biomarkers of hypopharyngeal squamous cell carcinoma. Zhonghua Yi Xue Za Zhi 86: 1484-8. (2006).

100

476. Detection of hypopharyngeal squamous cell carcinoma using serum proteomics. Acta Otolaryngol 126: 853-60. (2006).

100

477. Schizophrenia proteomics: biomarkers on the path to laboratory medicine? Diagn Pathol 1: 11. (2006).

100

478. Comparative analysis of whole saliva proteomes for the screening of biomarkers for oral li Inflamm Res 0: . (2006).

100

479. Proteomic analysis of the allograft response. Transplantation 82: 267-74. (2006).

100

480. Breast cancer prognosis by combinatorial analysis of gene expression data. Breast Cancer Res 8: R41. (2006).

100

481. Radiation-guided gene therapy of cancer. Technol Cancer Res Treat 5: 437-44. (2006).

100

482. Proteomics-based identification of secreted protein dihydrodiol dehydrogenase as a novel s Lung Cancer 0: . (2006).

100

483. Neuroproteomics: Relevance toAnxiety Disorders. Curr Psychiatry Rep 8: 286-90. (2006).

100

484. Emerging use of nanoparticles in diagnosis and treatment of breast cancer. Lancet Oncol 7: 657-67. (2006).

100

485. Diagnosis of early relapse in ovarian cancer using serum proteomic profiling. Genome Inform 16: 195-204. (2005).

100

486. Novel Application of ProteinChip Technology Exploring Acute Rejection Markers of Rat Small Transplantation 82: 320-6. (2006).

100

487. Use of proteomic patterns of serum biomarkers in patients with chronic obstructive pulmona Proc Am Thorac Soc 3: 465-6. (2006).

100

488. Biomarkers and multiple drug resistance in breast cancer. Curr Cancer Drug Targets 6: 365-84. (2006).

100

489. Clinically relevant oral cancer model for serum proteomic eavesdropping on the tumour micr J Otolaryngol 35: 157-66. (2006).

100

490. Contribution of genomics and proteomics in understanding the role of modifying factors in Indian J Biochem Biophys 43: 69-81. (2006).

100

491. Modern Tumor Marker Discovery in Urology: Surface Enhanced Laser Desorption and Ionization Rev Urol 5: 81-9. (2003).

100

492. Evaluation of apolipoprotein A1 and posttranslationally modified forms of transthyretin as Cancer Epidemiol Biomarkers Prev 15: 1641-6. (2006).

100

493. Collection, processing, and storage of biological samples in epidemiologic studies: sex ho Cancer Epidemiol Biomarkers Prev 15: 1578-81. (2006).

100

494. A path or a new road in laboratory diagnostics? Biological mass spectrometry: facts and pe Pathol Oncol Res 12: 178-83. (2006).

100

495. Proteomic identification of new biomarkers and application in thyroid cytology. Acta Cytol 50: 518-28. (0).

100

496. Interest of major serum protein removal for Surface-Enhanced Laser Desorption/Ionization - Proteome Sci 4: 20. (2006).

100

497. [Introduction of proteomic approach to environmental medicine] Nippon Eiseigaku Zasshi 61: 393-9. (2006).

100

498. Protein biomarkers associated with acute renal failure and chronic kidney disease. Eur J Clin Invest 36: 753-63. (2006).

100

499. Biomarkers in cardiovascular disease: integrating pathophysiology into clinical practice. Am J Med Sci 332: 186-97. (2006).

100

500. The application of genomic and proteomic technologies in predictive, preventive and person Vascul Pharmacol 0: . (2006).



من مواضيع faridhalim20 في المنتدى


التعديل الأخير تم بواسطة faridhalim20 ; 07-13-2008 الساعة 03:42 AM
التوقيع

عالم الموبليا يناديك

و علم الكيمياء الحيويه يحاكيك

   
رد مع اقتباس
 
 
إضافة رد


الذين يشاهدون محتوى الموضوع الآن : 1 ( الأعضاء 0 والزوار 1)
 
أدوات الموضوع
انواع عرض الموضوع

تعليمات المشاركة
لا تستطيع إضافة مواضيع جديدة
لا تستطيع الرد على المواضيع
لا تستطيع إرفاق ملفات
لا تستطيع تعديل مشاركاتك

BB code is متاحة
كود [IMG] متاحة
كود HTML معطلة

الانتقال السريع



الساعة الآن 05:08 AM


Powered by vBulletin® Version 3.8.7
Copyright ©2000 - 2018, vBulletin Solutions, Inc.
يوتك